查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829590

糖尿病護理設備市場（按設備類型、技術、交付方式、胰島素類型、分銷管道和最終用戶分類）—2025-2032 年全球預測

Diabetes Care Devices Market by Device Type, Technology, Delivery Mode, Insulin Type, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年糖尿病護理設備市場將成長至 125.8 億美元，複合年成長率為 19.11%。

主要市場統計數據
基準年2024年 31億美元
預計2025年 36.8億美元
預測年份：2032年 125.8億美元
複合年成長率（%） 19.11%

糖尿病護理設備領域正處於關鍵時刻，這得益於技術的快速成熟、醫療服務模式的轉變以及患者和付款人期望的不斷提升。感測器精度、演算法控制和無線互通性的進步，重新定義了臨床醫生和糖尿病患者對設備的期望：持續的洞察、可操作的自動化以及與日常生活和臨床工作流程的無縫整合。同時，醫療保健系統正在優先考慮治療結果和價值，推動報銷途徑和採購決策，優先考慮那些能夠顯著改善血糖控制、減少併發症並降低總護理成本的設備。

隨著這些力量的匯聚，製造商、技術合作夥伴和醫療保健提供者正在完善其產品藍圖和商業策略。創新日益以患者為中心，注重易用性、減輕設備負擔和數據透明度。監管機構正在不斷改進其指導方針，以適應軟體主導的療法和組合藥物，而供應鏈和製造考量如今在商業性可行性中發揮著至關重要的作用。總而言之，這些動態為一個加速顛覆的時代奠定了基礎，在這個時代，臨床有效性、連結性、監管敏捷性和營運彈性將決定市場主導。

閉合迴路自動化、即時連接、智慧交付選項和分散護理模式如何重塑糖尿病設備的開發和商業化

糖尿病照護設備領域正在經歷一場變革，重新定義治療模式和商業性模式。首先，結合持續感知和自動化胰島素輸送的閉合迴路系統已從利基研究原型轉變為具有商業性可行性的治療方案。因此，臨床路徑正在不斷調整，以納入演算法決策支援和遠端監控，護理也從偶發性診療轉變為持續性護理關係。

同時，連網型設備和雲端平台的普及創造了更豐富的縱向資料集，使更個人化的治療調整和人群層面的分析成為可能。此類數據的可用性促進了設備製造商、軟體開發商和付款方之間的夥伴關係，從而催生了一個互通性和安全數據交換為商業性差異化因素的生態系統。同時，智慧筆和先進注射輔助器具的興起也拓展了胰島素給藥的選擇，提供了彌合生活方式便利性和臨床有效性之間差距的選擇。遠端醫療、家庭診斷和遠距滴定正在減少對集中式診所的依賴，並由此重塑分銷策略、教育推廣和客戶支援模式。

評估 2025 年美國關稅及其對糖尿病醫療設備籌資策略、定價能力和製造足跡的連鎖影響

美國將在2025年之前徵收關稅，這已產生一系列累積效應，波及糖尿病護理設備採購、定價策略和供應鏈。依賴跨境採購的製造商正面臨不斷上升的投入成本，不得不立即重新評估籌資策略和供應商合約。一些公司正在透過加速近岸外包或多元化供應商來降低風險，而有些公司則正在尋求合約條款來分擔或吸收關稅相關成本。這些營運調整會影響生產前置作業時間和庫存管理，同時平衡成本控制和服務水準承諾。

從商業性角度來看，關稅給器械定價和報銷談判帶來了壓力。付款人和採購團體對單價和生命週期支出的關注度日益提高，從而影響了醫院和診所的處方決策和競標結果。一些製造商選擇暫時消化關稅影響以維持市場進入，而另一些製造商則實施了與特定產品線掛鉤的價格調整。同時，關稅環境反映出企業為降低貿易風險而採取的長期舉措，鼓勵對國內製造能力的投資以及與本地委託製造製造商建立策略聯盟。最終，關稅事件加速了採購、製造地決策和貿易條款的結構性轉變，這將對當前金融週期之外的競爭動態產生影響。

深度細分分析揭示了產品類型、感測和輸送技術、胰島素配方、通路和最終用戶偏好如何相互影響，從而形成產品策略

細緻的細分視角揭示了不同設備系列、技術、給藥方式、胰島素製劑、管道和最終用戶之間獨特的成長方向和差異化的臨床價值。按設備類型分類，市場構成涵蓋從採用全閉合迴路和混合閉合迴路架構的全自動人工胰腺系統，到涵蓋持續血糖監測、瞬時血糖監測和自我監測的血糖監測設備。注射輔助器具包括輸液器、筆式針頭和注射器針頭，而胰島素筆則包括預填充一次性筆、可重複使用筆和日益複雜的智慧筆。胰島素幫浦進一步分為貼片幫浦和管泵，兩者在穿戴性和儲液容量方面各有優劣。

從技術面來看，連續血糖監測本身可分為即時和回顧性連續血糖監測，它們不同於閃光血糖監測和自我監測方法。輸送模式可分為連續和間歇輸送，以適應不同的臨床特徵和患者偏好。胰島素類型從中效到超長效，常用的長效型如地特胰島素和甘精胰島素，以及速效型態如Aspart、賴谷胰島素和Lispro胰島素，其塑造設備相容性及給藥演算法。分銷管道包括直銷、醫院藥房、線上通路和零售藥局，零售藥局進一步分為連鎖藥局和獨立藥局。最後，最終用戶細分涵蓋診斷中心、居家醫療保健機構和醫院/診所，後者包括專門的糖尿病診所和全科醫生。

綜合起來，這些細分市場決定了產品設計重點、臨床定位和上市策略。例如，智慧筆和連續技術與居家醫療部署和線上銷售緊密相關，而混合和全閉合迴路系統在早期採用期間則需要醫院、糖尿病診所和專業診斷服務的全面支援。因此，製造商必須將其技術選擇與通路和最終用戶管道結合，以最佳化臨床效果和商業性應用。

對影響美洲、歐洲、中東和非洲以及亞太地區商業性成功的法規結構、報銷促進因素和採用途徑進行區域比較

區域動態顯著影響美洲、歐洲、中東和非洲以及亞太地區的監管和報銷框架及應用節奏。在美洲，對付款人模式和基於價值的合約的高度重視正促使製造商展示其成果和成本抵消。這有利於那些能夠顯著減少急性事件和醫院利用率的設備，並正在加速互聯系統在已建立覆蓋途徑的人群中的應用。相反，歐洲、中東和非洲呈現出多種多樣的管理體制和採購慣例。一些歐洲市場的集中核准和國內價格談判與其他司法管轄區的異質准入形成鮮明對比，因此需要差異化的市場進入和證據產生策略。

亞太市場呈現多樣化的需求促進因素。高人口密度和不斷上升的滲透率創造了規模化發展的機會，而報銷和收入水準的差異則要求提供分級產品和進行通路創新。在某些市場，本地製造夥伴關係和許可安排已成為規避進口關稅和獲得優先供應商地位的關鍵。一些國家正在迅速採用持續監測和閉合迴路方法，而其他國家則優先考慮經濟高效的間歇給藥解決方案和強大的供應鏈韌性。因此，製造商必須根據區域付款人的期望和監管現狀，客製化其臨床證據基礎、定價方法和夥伴關係模式，以最大限度地提高產品採用率和報銷成功率。

領先的糖尿病設備製造商的策略和競爭行動專注於平台整合、夥伴關係、證據生成和供應彈性

糖尿病設備領域的主要企業正在將產品創新與生態系統夥伴關係和資本約束相結合。關鍵的策略行動包括：擴展其平台，提供整合感測、交付和分析的端到端解決方案；與胰島素製造商和數位醫療公司建立垂直夥伴關係；以及選擇性地投資於製造能力，以更好地管理供應連續性。一些公司強調軟體即服務模式，將分析和護理管理功能與設備硬體一起收益；而另一些公司則透過更小的尺寸、更佳的穿戴式性和更好的用戶體驗來進一步提升其硬體的差異化。

競爭動態也受到併購、授權合約和共同開發契約的影響，這些協議可以加快複雜組合產品的上市時間。成功的公司往往將臨床證據生成納入其商業化計劃的早期階段，並將隨機和真實世界證據與付款人的決策需求相結合。此外，他們還會投資於客戶教育、專家培訓和上市後監測，以增強臨床可信度並減少器械損耗。最後，認知到採購團隊擴大將環境影響納入採購決策，越來越多的公司正在考慮製造和包裝的永續性，並將聲譽和成本納入考慮。

設備製造商需要採取切實可行的策略措施，協調臨床價值、供應彈性、互通性和區域商業化方法，以實現持續成長

行業領導者應採取一系列切實可行的行動，確保在技術加速發展和付款人審查日益嚴格的市場環境中保持持久優勢。首先，優先考慮端到端的臨床價值，將產品設計與對付款人和提供者至關重要的可衡量結果相結合，並將證據生成嵌入產品生命週期，以加快報銷時間。其次，透過結合近岸製造選項和多層級供應商協議，實現供應鏈多元化，以減輕關稅和零件中斷的影響。第三，透過投資互通性和開放標準，確保產品能夠整合到電子健康記錄和人口健康管理平台中，從而提高醫療系統的採用率。

第四，開發分級商業產品，以滿足不同地區不同的可負擔性需求，將高階、完全整合的系統與針對資源匱乏市場的簡化、經濟高效的替代方案相結合。第五，與胰島素製造商、數位療法公司和遠端保健提供者建立策略夥伴關係，打造捆綁式解決方案，協調相關人員的獎勵機制。第六，加速支持臨床醫師培訓和病患入職的上市後項目，減少實施阻力，提高病患留存率。這些努力將有助於製造商應對複雜的法規，滿足不斷變化的臨床預期，並在日益以結果為導向的市場中佔據長期佔有率。

透過嚴格的混合方法研究檢驗見解和建議，該研究將監管、臨床和商業性證據與專家訪談和情境分析相結合

本報告採用混合方法整合證據，將全面的二手資料研究與一手質性研究結合，以確保研究的穩健性。二手資料包括監管備案文件、同行評審臨床文獻、公司技術揭露和政策聲明，以建立事實和監管背景。一手資料研究包括與臨床意見領袖、採購專家和高級商務主管進行的結構化訪談，以及與付款人和糖尿病護理協調員進行有針對性的討論，以檢驗商業和報銷動態。

分析過程包括：將定性檢驗與已發表的臨床結果和監管指南進行交叉驗證；情境分析以對關稅和供應中斷的影響進行壓力測試；以及對訪談結果進行主題編碼，以突出反復出現的應用障礙和促成因素。品質保證步驟包括由主題專家進行獨立審查，並協調差異以得出平衡的結論。研究行為始終遵循倫理道德和資料隱私通訊協定，專有商業資訊得到保密處理，並且盡可能將綜合結果反映為共識，而非單一來源的斷言。

綜合策略要務強調向綜合、主導糖尿病護理解決方案的過渡以及擴大規模所需的營運彈性

總而言之，糖尿病護理設備產業正從漸進式改進轉向由自動化、互聯互通和不斷變化的護理模式所驅動的系統級轉型。那些擺脫以產品為中心、擁抱能夠提供可衡量臨床和經濟價值的整合解決方案的相關人員，將最有可能抓住新的機會。同時，透過多元化供應鏈、區域製造夥伴關係和積極的關稅減免所展現的營運韌性，正成為競爭的必需品，而非僅僅是後勤部門事務。

未來的成功取決於能否將醫療設備產生的大量數據轉化為切實可行的臨床工作流程，能否透過強力的證據包確保支付方的一致性，能否提供根據當地情況量身定做的靈活商業模式。對於製造商、投資者和醫療保健系統而言，我們的使命非常明確：追求創新，使糖尿病護理更簡單、更安全、更便捷，同時建立商業性和營運實力，以擴大規模並交付這些創新。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 透過整合持續血糖監測和人工智慧預測分析平台實現主動血糖控制
  • 利用光譜技術和微針陣列開發非侵入式血糖監測感測器
  • 封閉回路型胰島素輸送系統的出現，將自動輸送演算法與個人數據回饋結合
  • 透過藍牙連接擴展遠端醫療胰島素筆，實現遠端劑量追蹤和藥物依從性監測
  • 投資多參數穿戴式生物感測器，同時監測血糖值、心率和活動指標
  • FDA核准雙激素人工胰臟原型，透過封閉回路型系統輸送胰島素和升糖素
  • 採用標準化互通性通訊協定，將 CGM 數據整合到各種糖尿病管理應用程式和電子健康記錄中
  • 以患者為中心的設備設計不斷發展，重點關注穿戴舒適度以及針對老年人和兒科用戶的簡化介面

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

第 8 章糖尿病護理設備市場（按設備類型）

  • 人工胰臟系統
    • 完全封閉回路型
    • 混合閉合迴路
  • 血糖監測裝置
    • 持續血糖監測
    • Flash血糖監測
    • 血糖自我監測
  • 注射輔助器
    • 點滴器
    • 筆針
    • 針頭
  • 胰島素筆
    • 一次性注射筆（預填充）
    • 可重複使用的筆
    • 智慧筆
  • 胰島素幫浦
    • 貼片幫浦
    • 管泵
  • 胰島素注射器

第9章糖尿病治療設備市場：按技術

  • 持續血糖監測
    • 即時連續血糖監測
    • 回顧性持續血糖監測
  • Flash血糖監測
  • 血糖自我監測
    • 血糖值監測儀
    • 《採血針》
    • 測試紙

第 10 章糖尿病治療設備市場（依給藥方式）

  • 持續給藥
  • 間歇給藥

第 11 章糖尿病治療設備市場（按胰島素類型）

  • 中效型
  • 長效
    • 地特米爾
    • 甘精胰島素
  • 快速起效
    • Aspart
    • Glulisine
    • Lispro
  • 短效
  • 超長效

第 12 章糖尿病護理設備市場（依通路）

  • 直銷
  • 醫院藥房
  • 線上管道
  • 零售藥局
    • 連鎖藥局
    • 獨立藥房

第13章糖尿病護理設備市場（依最終用戶）

  • 診斷中心
  • 居家醫療
  • 醫院和診所
    • 糖尿病診所
    • 綜合診所

第 14 章糖尿病治療設備市場：按地區

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章糖尿病護理設備市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章糖尿病照護設備市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • Medtronic plc
    • Roche Holding AG
    • Dexcom, Inc.
    • Becton, Dickinson and Company
    • Insulet Corporation
    • Tandem Diabetes Care, Inc.
    • Terumo Corporation
    • Kyowa Kirin Co., Ltd.
    • Ypsomed Holding AG
Product Code: MRR-43539E5D2EA5

The Diabetes Care Devices Market is projected to grow by USD 12.58 billion at a CAGR of 19.11% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.10 billion
Estimated Year [2025] USD 3.68 billion
Forecast Year [2032] USD 12.58 billion
CAGR (%) 19.11%

The diabetes care devices landscape is at a pivotal moment, driven by rapid technological maturation, shifting care delivery models, and intensifying expectations from patients and payers alike. Advances in sensor accuracy, algorithmic control, and wireless interoperability have recalibrated what clinicians and people living with diabetes expect from devices: continuous insights, actionable automation, and seamless integration into daily life and clinical workflows. At the same time, healthcare systems are emphasizing outcomes and value, prompting reimbursement pathways and procurement decisions to prioritize devices that demonstrably improve glycemic control, reduce complications, and lower total cost of care.

As these forces converge, manufacturers, technology partners, and healthcare providers are refining product roadmaps and commercial strategies. Innovation is increasingly patient-centric, focusing on ease of use, reduced device burden, and data transparency. Regulatory authorities are evolving guidance to accommodate software driven therapeutics and combination products, while supply chain and manufacturing considerations now play an outsized role in commercial viability. Taken together, these dynamics set the stage for a period of accelerated disruption where clinical efficacy, connectivity, regulatory agility, and operational resilience will determine market leadership.

How closed-loop automation, real-time connectivity, smart delivery options, and decentralized care models are reshaping diabetes device development and commercialization

The landscape of diabetes care devices has undergone transformative shifts that are redefining therapeutic paradigms and commercial playbooks. First, closed-loop systems that combine continuous sensing with automated insulin delivery have transitioned from niche research prototypes to commercially viable therapeutic options. As a result, clinical pathways are adapting to incorporate algorithmic decision support and remote monitoring, moving care from episodic encounters to continuous care relationships.

Concurrently, the proliferation of connected devices and cloud platforms has created richer longitudinal datasets that enable more personalized therapy adjustments and population-level analytics. This data availability is catalyzing partnerships between device manufacturers, software developers, and payers, fostering an ecosystem where interoperability and secure data exchange are commercial differentiators. In parallel, the rise of smart pens and advanced injection aids has broadened the options for insulin delivery, offering alternatives that can bridge the gap between lifestyle convenience and clinical efficacy. Finally, the industry is witnessing a shift toward decentralization of care: telehealth, home diagnostics, and remote titration are reducing the reliance on centralized clinics, and in doing so, reshaping distribution strategies, educational outreach, and customer support models.

Assessment of the 2025 United States tariff measures and their cascading effects on sourcing strategies, pricing dynamics, and manufacturing footprints across diabetes devices

The imposition of tariffs in the United States during 2025 has introduced a set of cumulative effects that ripple across procurement, pricing strategies, and supply chains for diabetes care devices. Manufacturers that rely on cross-border component sourcing have encountered escalated input costs, prompting immediate reassessment of sourcing strategies and supplier contracts. In response, some organizations accelerated nearshoring initiatives or diversified supplier bases to mitigate exposure, while others sought contractual clauses to share or absorb tariff related costs. These operational adjustments have implications for production lead times and inventory management as firms balance cost containment with service level commitments.

From a commercial perspective, tariffs have created pressure on device pricing and reimbursement negotiations. Payers and purchasing groups have become more vigilant about unit costs and lifecycle expenditures, which in turn influences formulary decisions and tender outcomes for hospitals and clinics. Some manufacturers opted to absorb tariff impacts temporarily to preserve market access, while others introduced price adjustments tied to specific product lines. At the same time, the tariff environment has incentivized investment in domestic manufacturing capabilities and strategic partnerships with local contract manufacturers, reflecting a longer-term pivot to reduce trade risk. Ultimately, the tariff episode accelerated structural shifts in sourcing, manufacturing footprint decisions, and commercial terms that will influence competitive dynamics beyond the immediate fiscal cycle.

Deep segmentation analysis revealing how device type, sensing and delivery technologies, insulin formulations, channels, and end user settings intersect to shape product strategies

A nuanced view of segmentation reveals divergent growth vectors and differentiated clinical value across device families, technologies, delivery modes, insulin formulations, channels, and end users. When examined by device type, the market composition ranges from fully automated artificial pancreas systems comprising full closed loop and hybrid closed loop architectures to glucose monitoring devices that cover continuous glucose monitoring, flash glucose monitoring, and self-monitoring blood glucose. The injection aids spectrum includes infusion sets, pen needles, and syringe needles, while insulin pens span prefilled disposable pens, reusable pens, and increasingly sophisticated smart pens. Insulin pumps are further categorized into patch pumps and tubed pumps, each offering distinct tradeoffs in wearability and reservoir capacity.

Looking through a technology lens, continuous glucose monitoring itself bifurcates into real-time continuous glucose monitoring and retrospective continuous glucose monitoring, and remains distinct from flash glucose monitoring and self-monitoring blood glucose approaches; the latter includes glucose meters, lancets, and test strips. Delivery mode segmentation divides offerings into continuous delivery and intermittent delivery, which align to different clinical profiles and patient preferences. Insulin types span intermediate acting through ultra long acting formulations, with commonly used long acting analogues such as detemir and glargine and rapid acting analogues including aspart, glulisine, and lispro shaping device compatibility and dosing algorithms. Distribution channel dynamics encompass direct sales, hospital pharmacies, online channels, and retail pharmacies, with retail channels further split between chain and independent pharmacies. Finally, end user segmentation covers diagnostic centers, home care settings, and hospitals and clinics, where the latter includes specialized diabetes clinics as well as general clinics.

Taken together, these segmentation layers intersect to inform product design priorities, clinical positioning, and go-to-market approaches. For example, smart pens and continuous technologies align strongly with home care adoption and online distribution, while hybrid and full closed loop systems require integrated support from hospitals, diabetes clinics, and specialized diagnostic services during early adoption phases. Manufacturers should therefore map technology choices to distribution and end user pathways to optimize clinical impact and commercial uptake.

Comparative regional intelligence on regulatory frameworks, reimbursement drivers, and adoption pathways across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine commercial success

Regional dynamics materially influence regulatory pathways, reimbursement frameworks, and adoption tempos across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, payer models and a strong emphasis on value-based contracting have pushed manufacturers to demonstrate outcomes and cost offsets. This has favored devices that enable measurable reductions in acute events and hospital utilization, and has accelerated uptake of connected systems in populations with established coverage pathways. Conversely, Europe, Middle East & Africa presents a mosaic of regulatory regimes and procurement practices; centralized approvals and national pricing negotiations in some European markets contrast with heterogeneous access in other jurisdictions, requiring differentiated market entry and evidence generation strategies.

Asia-Pacific markets exhibit diverse demand drivers, where high population density and rising prevalence create scale opportunities, while variable reimbursement and income levels necessitate tiered product offerings and channel innovation. In several markets, local manufacturing partnerships and licensing arrangements have been critical to navigating import duties and securing preferred provider status. Across regions, technology adoption curves differ: while some countries rapidly embrace continuous monitoring and closed-loop approaches, others prioritize cost-effective intermittent delivery solutions and robust supply chain resilience. Manufacturers should therefore calibrate clinical evidence dossiers, pricing approaches, and partnership models in accordance with regional payer expectations and regulatory realities to maximize adoption and reimbursement success.

Strategic behaviors and competitive moves among leading diabetes device manufacturers focused on platform integration, partnerships, evidence generation, and supply resilience

Leading companies in the diabetes devices space are aligning product innovation with ecosystem partnerships and capital discipline. Key strategic behaviors include platform expansion to deliver end-to-end solutions that combine sensing, delivery, and analytics; vertical partnerships with insulin manufacturers and digital health firms; and selective investments in manufacturing capabilities to enhance control over supply continuity. Some organizations emphasize software as a service models, monetizing analytics and care management features alongside device hardware, while others double down on hardware differentiation through miniaturization, improved wearability, and enhanced user experience.

Competitive dynamics are also shaped by M&A, licensing, and co-development agreements that accelerate time to market for complex combination products. Companies that succeed tend to integrate clinical evidence generation into commercialization plans early, aligning randomized and real-world evidence to payer decision needs. Additionally, leaders invest in customer education, professional training, and post-market surveillance to reinforce clinical trust and reduce device attrition. Finally, a growing number of firms are committing to sustainability in manufacturing and packaging as a reputational and cost consideration, recognizing that procurement teams increasingly factor environmental impact into purchasing decisions.

Actionable strategic imperatives for device manufacturers to align clinical value, supply resilience, interoperability, and regional commercialization approaches for sustained growth

Industry leaders should pursue a set of pragmatic actions to secure durable advantage in a landscape defined by technological acceleration and payer scrutiny. First, prioritize end-to-end clinical value by aligning product design with measurable outcomes that matter to payers and providers, and embed evidence generation in product lifecycles to shorten reimbursement timelines. Second, diversify supply chains by combining nearshore manufacturing options with multi-tier supplier agreements to mitigate tariff exposure and component disruptions. Third, invest in interoperability and open standards to ensure devices can integrate into electronic health records and population health platforms, thereby increasing adoption by health systems.

Fourth, develop tiered commercial offerings that address distinct regional affordability profiles, pairing premium, fully integrated systems with simplified, cost-effective alternatives for resource constrained markets. Fifth, cultivate strategic partnerships with insulin producers, digital therapeutics firms, and telehealth providers to create bundled solutions that align incentives across stakeholders. Sixth, accelerate post-market programs that support clinician training and patient onboarding, reducing friction in adoption and improving retention. Together, these actions will enable manufacturers to navigate regulatory complexities, respond to evolving clinical expectations, and capture long-term share in an increasingly outcomes-oriented market.

Rigorous mixed methods research combining regulatory, clinical, and commercial evidence with expert interviews and scenario analysis to validate insights and recommendations

This report synthesizes evidence using a mixed-methods approach that combines comprehensive secondary research with primary qualitative inquiry and triangulation to ensure robustness. Secondary inputs include regulatory filings, peer-reviewed clinical literature, company technical disclosures, and policy announcements that establish the factual backdrop and regulatory context. Primary research incorporated structured interviews with clinical opinion leaders, procurement specialists, and senior commercial executives, along with targeted discussions with payers and diabetes care coordinators to validate commercial and reimbursement dynamics.

Analytical processes included cross-validation of qualitative insights against published clinical outcomes and regulatory guidance, scenario analysis to stress test the implications of tariffs and supply disruptions, and thematic coding of interview outputs to surface recurring adoption barriers and enablers. Quality assurance steps encompassed independent review by subject matter experts and reconciliation of divergent viewpoints to create balanced conclusions. Ethical research conduct and data privacy protocols were maintained throughout, ensuring that proprietary commercial information was handled under confidentiality and that synthesized findings reflect consensus where possible rather than single-source assertions.

Synthesis of strategic imperatives underscoring the transition to integrated, evidence-driven diabetes care solutions and the operational resilience required for scale

In conclusion, the diabetes care devices sector is transitioning from incremental improvement to systems-level transformation, driven by automation, connectivity, and shifting care paradigms. Stakeholders who move beyond product centric thinking to embrace integrated solutions that deliver measurable clinical and economic value will be best positioned to capture emerging opportunities. At the same time, operational resilience-manifested through diversified supply chains, regional manufacturing partnerships, and proactive tariff mitigation-has become a competitive necessity rather than a back-office concern.

Looking ahead, success will hinge on the ability to translate rich device-generated data into actionable clinical workflows, to secure payer alignment through strong evidence packages, and to offer flexible commercial models adapted to regional contexts. For manufacturers, investors, and healthcare systems alike, the mandate is clear: pursue innovations that make diabetes care simpler, safer, and more accessible, while building the commercial and operational muscle to deliver those innovations at scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of continuous glucose monitoring with AI-powered predictive analytics platforms for proactive glycemic control
  • 5.2. Development of non-invasive glucose monitoring sensors utilizing spectroscopic technologies and microneedle arrays
  • 5.3. Emergence of closed-loop insulin delivery systems combining automated dosing algorithms and personalized data feedback
  • 5.4. Expansion of telehealth-enabled insulin pens with Bluetooth connectivity for remote dose tracking and adherence monitoring
  • 5.5. Investment in multi-parameter wearable biosensors for simultaneous monitoring of glucose, heart rate and activity metrics
  • 5.6. FDA clearance trends for bi-hormonal artificial pancreas prototypes delivering both insulin and glucagon through closed-loop systems
  • 5.7. Adoption of standardized interoperability protocols to integrate CGM data across diverse diabetes management apps and electronic health records
  • 5.8. Growth of patient-centric device designs focusing on wearable comfort and simplified interfaces for elderly and pediatric users

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diabetes Care Devices Market, by Device Type

  • 8.1. Artificial Pancreas Systems
    • 8.1.1. Full Closed Loop
    • 8.1.2. Hybrid Closed Loop
  • 8.2. Glucose Monitoring Devices
    • 8.2.1. Continuous Glucose Monitoring
    • 8.2.2. Flash Glucose Monitoring
    • 8.2.3. Self Monitoring Blood Glucose
  • 8.3. Injection Aids
    • 8.3.1. Infusion Sets
    • 8.3.2. Pen Needles
    • 8.3.3. Syringe Needles
  • 8.4. Insulin Pens
    • 8.4.1. Prefilled Disposable Pens
    • 8.4.2. Reusable Pens
    • 8.4.3. Smart Pens
  • 8.5. Insulin Pumps
    • 8.5.1. Patch Pumps
    • 8.5.2. Tubed Pumps
  • 8.6. Insulin Syringes

9. Diabetes Care Devices Market, by Technology

  • 9.1. Continuous Glucose Monitoring
    • 9.1.1. Real Time Continuous Glucose Monitoring
    • 9.1.2. Retrospective Continuous Glucose Monitoring
  • 9.2. Flash Glucose Monitoring
  • 9.3. Self Monitoring Blood Glucose
    • 9.3.1. Glucose Meters
    • 9.3.2. Lancets
    • 9.3.3. Test Strips

10. Diabetes Care Devices Market, by Delivery Mode

  • 10.1. Continuous Delivery
  • 10.2. Intermittent Delivery

11. Diabetes Care Devices Market, by Insulin Type

  • 11.1. Intermediate Acting
  • 11.2. Long Acting
    • 11.2.1. Detemir
    • 11.2.2. Glargine
  • 11.3. Rapid Acting
    • 11.3.1. Aspart
    • 11.3.2. Glulisine
    • 11.3.3. Lispro
  • 11.4. Short Acting
  • 11.5. Ultra Long Acting

12. Diabetes Care Devices Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Hospital Pharmacies
  • 12.3. Online Channels
  • 12.4. Retail Pharmacies
    • 12.4.1. Chain Pharmacies
    • 12.4.2. Independent Pharmacies

13. Diabetes Care Devices Market, by End User

  • 13.1. Diagnostic Centers
  • 13.2. Home Care
  • 13.3. Hospitals And Clinics
    • 13.3.1. Diabetes Clinics
    • 13.3.2. General Clinics

14. Diabetes Care Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Diabetes Care Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Diabetes Care Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. Medtronic plc
    • 17.3.3. Roche Holding AG
    • 17.3.4. Dexcom, Inc.
    • 17.3.5. Becton, Dickinson and Company
    • 17.3.6. Insulet Corporation
    • 17.3.7. Tandem Diabetes Care, Inc.
    • 17.3.8. Terumo Corporation
    • 17.3.9. Kyowa Kirin Co., Ltd.
    • 17.3.10. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES CARE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. DIABETES CARE DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. DIABETES CARE DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DIABETES CARE DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DIABETES CARE DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES CARE DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COU